Ronaldo Go, MD
Pulmonary Disease · Hackensack, NJNPI 1336335710
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,390 of the $1,642 with a category attached, or 84.7%. Genentech, Inc. accounts for 84.7% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2020 at $1,405 and has fallen 98.3% since, to $24 in 2025. That places this record below the midpoint for pulmonary disease clinicians in NJ, where the typical reported total is $2,135.
Across 11 payments — averaging $149.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$1K
- AstraZeneca$125
- Gilead$54
- CSL Behring$24
- Johnson & Johnson$19
- Pfizer$15
- plus $15 from 1 others
Across 15 payments — averaging $37,445 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Products Limited$542K
- Genentech, Inc.$20K
What the payments were for
- Consulting fees$1,39085%
- Food & beverage$23815%
- Education$141%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 2 | $1,390 |
| AstraZeneca | 1 | $125 |
| Gilead | 4 | $54 |
| CSL Behring | 1 | $24 |
| Johnson & Johnson | 1 | $19 |
| Pfizer | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,642 in reported general payments places this provider in the 45th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Hackensack
- Emanuele SantomauroHackensack$420K
- Nadeem AliHackensack$110K
- John VillaHackensack$15K
- David OrrHackensack$14K
- Joseph HoffmanPark Ridge$1.1M
- Reynold PanettieriNew Brunswick$1M
- Robert SussmanSummit$551K
- Manuel CunananMillville$489K
- Richard MillerNewark$328K
- Jason ShatkinParamus$282K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.